美国食品和药物管理局敦促制造商用与人类相关的方法代替动物试验, 如有机体和计算机模型, 由1.5亿美元的国家卫生研究院资助. The FDA urges drugmakers to replace animal testing with human-relevant methods like organoids and computer models, backed by $150M NIH funding.

美国食品和药物管理局已发布指导草案,敦促制药公司采用与人类相关的非动物试验方法 (如器官体,计算机模拟以及实验室培养组织) 以提高药物的开发准确性和道德. The FDA has released draft guidance urging pharmaceutical companies to adopt human-relevant, non-animal testing methods—such as organoids, computer simulations, and lab-grown tissues—to improve drug development accuracy and ethics. 这一举措旨在减少对动物试验的依赖, 往往无法预测人类反应, 并支持更快, 更具成本效益的研究. The move aims to reduce reliance on animal testing, which often fails to predict human responses, and supports faster, more cost-effective research. 美国国家卫生研究院承诺提供1.5亿美元用于推进这些替代方案. The NIH pledged $150 million to advance these alternatives. 该指南概述了新方法方法 (NAM) 的验证原则,并鼓励与FDA审查小组合作. The guidance outlines validation principles for new approach methodologies (NAMs) and encourages collaboration with FDA review teams.